Pliant snags $287.5 million in oversubscribed public offering amid market uncertainty
Pliant Therapeutics' recent fundraise to boost its rare disease pipeline comes when experts predict a challenging public market.
Knowledge Bank
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox